Table 2.
Correlation between p16 expression and HPV status of all patients with head and neck cancers and those with oropharyngeal cancer
| All patients N = 348 |
OPSCC patients N = 64 |
Non-OPSCC patients N = 284 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| HPV+ n = 14 (%) |
HPV- n = 334 (%) |
p-value | HPV+ n = 10 (%) |
HPV- n = 54 (%) |
p-value | HPV+ n = 4 (%) |
HPV- n = 280 (%) |
p-value | |||
|
p16+ n = 40 (%) |
9 (64) | 31 (9) | < 0.001 |
p16+ n = 21 (%) |
8 (80) | 13 (24) | 0.001 |
p16+ n = (%) |
1 (25) | 18 (6) | 0.243 |
|
p16- n = 308 (%) |
5 (36) | 303 (91) |
p16- n = 43 (%) |
2 (20) | 41 (76) |
p16- n = (%) |
3 (75) | 262 (94) | |||
| p16 testing when using HPV DNA as a gold standard | |||||||||||
| Sensitivity | 64% | Sensitivity | 80% | Sensitivity | 25% | ||||||
| Specificity | 91% | Specificity | 76% | Specificity | 94% | ||||||
| False positive | 9% | False positive | 24% | False positive | 6% | ||||||
| False negative | 36% | False negative | 20% | False negative | 75% | ||||||
| Positive predictive rate | 22% | Positive predictive rate | 38% | Positive predictive rate | 5% | ||||||
| Negative predictive rate | 98% | Negative predictive rate | 95% | Negative predictive rate | 99% | ||||||
| Discordant rate | 10% | Discordant rate | 23% | Discordant rate | 7% | ||||||